While preclinical studies have demonstrated the anti-tumor potential of MYBL2-targeted therapies, including small-molecule inhibitors and CRISPR-based gene editing (13), challenges persist regarding specificity and off-target effects. The gene discussed is MYBL2; the disease is neoplasm.